Torge Rempe

Torge Rempe, MD, PhD

Assistant Professor

Department: MD-NEURO-MULTIPLE SCLEROSIS
Business Phone: (352) 294-5000
Business Email: torgerempe@ufl.edu

About Torge Rempe

I am an assistant professor with the department of neurology at the University of Florida College of Medicine. Additionally, I am the William T. and Janice M. Neely professor for research in multiple sclerosis. I attended medical school at the Christian-Albrecht University of Kiel in Germany, with one year spent at the University of Murcia in Spain. I graduated with my medical degree in 2012, then pursued my postgraduate neurology training in Germany at the University Hospital of Schleswig-Holstein.

After my preliminary year at SUNY Downstate Medical Center in New York, I completed my neurology residency at the University of Florida. The following year, I finished my clinical neuroimmunology fellowship at the University of California San Diego.

I am board-certified in neurology by the American Board of Psychiatry and Neurology, and I am licensed to practice medicine in both Florida and California. My clinical and research interests include multiple sclerosis, neurosarcoidosis, neuroimmunology, neuromyelitis optica, MOG antibody disease and autoimmune encephalitis. I have contributed to many publications, as well as speak German, English and Spanish.

Accomplishments

Kenneth M. Heilman Award for Excellence in Research
2020 · UF Department of Neurology
Program Director’s Award for Academic Excellence
2018-2020 · UF Department of Neurology

Teaching Profile

Courses Taught
2022-2024
PAS5020 Intro to Medicine 2

Board Certifications

  • Neurology
    American Board of Psychiatry and Neurology

Clinical Profile

Specialties
  • Neurology
Areas of Interest
  • Multiple sclerosis
  • Neurosarcoidosis
  • Stroke

Research Profile

Areas of Interest
  • Antibodies
  • Multiple Sclerosis
  • Neuroimmunology
  • Neuroinflammation
Open Researcher and Contributor ID (ORCID)

0000-0003-0538-1378

Publications

2024
Frequency, characteristics, predictors and treatment of relapsing myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD)
Multiple Sclerosis and Related Disorders. 87 [DOI] 10.1016/j.msard.2024.105672.
2024
Multiple Sclerosis: Clinical Update and Clinically-Oriented Radiologic Reporting.
Magnetic resonance imaging clinics of North America. 32(2):363-374 [DOI] 10.1016/j.mric.2024.01.001. [PMID] 38555146.
2024
Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Magnetic resonance imaging clinics of North America. 32(2):233-251 [DOI] 10.1016/j.mric.2023.12.001. [PMID] 38555139.
2023
Ocrelizumab B-cell repopulation-guided extended interval dosing versus standard dosing – similar clinical efficacy with decreased immunoglobulin M deficiency rates
Multiple Sclerosis and Related Disorders. 79 [DOI] 10.1016/j.msard.2023.105028.
2023
Progressive multifocal leukoencephalopathy without overt immunosuppression
Medicine. 102(39) [DOI] 10.1097/md.0000000000035265.
2022
A Comparison of Pediatric- and Adult-Onset Aquaporin-4 Immunoglobulin G-Positive Neuromyelitis Optica Spectrum Disorder: A Review of Clinical and Radiographic Characteristics.
Journal of child neurology. 37(8-9):727-737 [DOI] 10.1177/08830738221103085. [PMID] 35673711.
2022
Longitudinal evaluation of neurologic-post acute sequelae SARS-CoV-2 infection symptoms.
Annals of clinical and translational neurology. 9(7):995-1010 [DOI] 10.1002/acn3.51578. [PMID] 35702954.
2022
Therapeutic Advances in Multiple Sclerosis.
Frontiers in neurology. 13 [DOI] 10.3389/fneur.2022.824926. [PMID] 35720070.
2021
Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
Multiple sclerosis and related disorders. 48 [DOI] 10.1016/j.msard.2020.102718. [PMID] 33388560.
2021
CNS Lymphocytic Vasculitis in a Young Woman With COVID-19 Infection
Neurology Neuroimmunology & Neuroinflammation. 8(5) [DOI] 10.1212/nxi.0000000000001048.
2021
Quantification of smooth pursuit dysfunction in multiple sclerosis
Multiple Sclerosis and Related Disorders. 54 [DOI] 10.1016/j.msard.2021.103073.
2020
“Status myotonicus” in Nav1.4-M1592V channelopathy.
Neuromuscular disorders : NMD. 30(5):424-426 [DOI] 10.1016/j.nmd.2020.03.002. [PMID] 32327288.
2020
Anti-JCV antibody index does not change during ocrelizumab-treatment
Multiple Sclerosis Journal – Experimental, Translational and Clinical. 6(3) [DOI] 10.1177/2055217320960510. [PMID] 33029356.
2020
Corticosteroids lead to short-term improvement in cerebral amyloid angiopathy-related inflammation.
Journal of neuroimmunology. 348 [DOI] 10.1016/j.jneuroim.2020.577377. [PMID] 32919147.
2020
Dorsal Root Ganglion Stimulation as a Potentially Effective Treatment for Painful Hereditary and Idiopathic Axonal Polyneuropathy: A Retrospective Case Series.
Neuromodulation : journal of the International Neuromodulation Society. 23(2):234-238 [DOI] 10.1111/ner.12924. [PMID] 30762923.
2020
Progressive multifocal leukoencephalopathy and granule cell neuronopathy with novel mutation flanking VP1 C-terminus in natalizumab-extended interval dosing.
Neurology(R) neuroimmunology & neuroinflammation. 7(3) [DOI] 10.1212/NXI.0000000000000709. [PMID] 32198230.
2019
A case of CLIPPERS syndrome responsive to tocilizumab.
Neurology(R) neuroimmunology & neuroinflammation. 6(3) [DOI] 10.1212/NXI.0000000000000545. [PMID] 30882019.
2019
Neurofascin‐140 and ‐155 antibodies in an atypical case of poems syndrome
Muscle & Nerve. 60(1) [DOI] 10.1002/mus.26493.
2019
The spectrum of progressive multifocal leukoencephalopathy: a practical approach
European Journal of Neurology. 26(4) [DOI] 10.1111/ene.13906.
2016
Early-onset parkinsonism due to compound heterozygous POLG mutations.
Parkinsonism & related disorders. 29:135-7 [DOI] 10.1016/j.parkreldis.2016.04.020. [PMID] 27185166.
2016
Sensitization of the Nociceptive System in Complex Regional Pain Syndrome.
PloS one. 11(5) [DOI] 10.1371/journal.pone.0154553. [PMID] 27149519.
2015
Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate.
Annals of neurology. 78(4):501-14 [DOI] 10.1002/ana.24471. [PMID] 26150206.
2015
Spinal and supraspinal processing of thermal stimuli: an fMRI study.
Journal of magnetic resonance imaging : JMRI. 41(4):1046-55 [DOI] 10.1002/jmri.24627. [PMID] 24737401.
2014
Spinal fMRI reveals decreased descending inhibition during secondary mechanical hyperalgesia.
PloS one. 9(11) [DOI] 10.1371/journal.pone.0112325. [PMID] 25372292.

Grants

Feb 2023 ACTIVE
CTOA Rempe – Residuals ?
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Aug 2022 ACTIVE
AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Na?ve, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes
Role: Principal Investigator
Funding: NOVARTIS PHARMACEUTICALS CORP
Jun 2022 ACTIVE
A Phase III, Randomized, Double Blind, Placebo controlled, Multi center Study To Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab as Monotherapy or in Addition to Baseline Therapy in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Role: Principal Investigator
Funding: SYNEOS HEALTH via GENENTECH INC
May 2022 ACTIVE
A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib
Role: Principal Investigator
Funding: NOVARTIS PHARMACEUTICALS CORP
Apr 2022 ACTIVE
A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)
Role: Principal Investigator
Funding: SANOFI
Mar 2022 – Aug 2023
A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio) in participants with relapsing forms of multiple sclerosis (GEMINI 2)
Role: Principal Investigator
Funding: SANOFI
Jan 2022 ACTIVE
A PHASE 3B, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE IMMUNE RESPONSE TO, AND THE SAFETY OF, VACCINES IN PARTICIPANTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS WHO RECEIVE ORAL OZANIMOD COMPARED TO NON-PEGYLATED INTERFERON-B OR NO DISEASE MODIFYING THERAPY
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC via CELGENE CORP
Apr 2019 ACTIVE
TRADITIONAL VERSUS EARLY AGGRESSIVE THERAPY FOR MULTIPLE SCLEROSIS (TREAT-MS) TRIAL
Role: Principal Investigator
Funding: JOHNS HOPKINS UNIVERSITY via NATL MULTIPLE SCLEROSIS SOC
Jul 2018 ACTIVE
A pragmatic trial to evaluate the intermediate-term effects of early, aggressive versus escalation therapy in people with multiple sclerosis
Role: Principal Investigator
Funding: JOHNS HOPKINS UNIVERSITY via PATIENT-CENTERED OUTCOMES RES INST
Nov 2017 ACTIVE
CMSC has created the North American Registry for Care and Research in Multiple Sclerosis
Role: Principal Investigator
Funding: CONSORTIUM OF MS CENTERS

Education

Fellowship, Neuroimmunology
2020-2021 · University of California San Diego
Residency, Neurology
2017-2020 · University of Florida
Medical Degree
2005-2012 · Christian-Albrecht University of Kiel

Contact Details

Phones:
Business:
(352) 294-5000
Emails:
Business:
torgerempe@ufl.edu
Addresses:
Business Mailing:
PO Box 100268
GAINESVILLE FL 32610
Business Street:
3011 SW WILLISTON RD RM 1103
GAINESVILLE FL 32608